GM-CSF R alpha Molekülinformation
Molecule Name
Granulocyte-macrophage colony-stimulating factor receptor subunit alpha
Molekülalias
GM-CSF R alpha,GM-CSF-R-alpha,GMCSFR-alpha,GMR-alpha,CSF2RA,CSF2R,CSF2RY,CDw116,CD116
Drug Development Progress
Anzahl der klinischen Arzneimittel4
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 3 Clinical
Target-Alias
GM-CSF-R-alpha，GMCSFR-alpha，GMR-alpha，CD116，Colony Stimulating Factor 2 Receptor Subunit Alpha，Colony Stimulating Factor 2 Receptor， Alpha， Low-Affinity (Granulocyte-Macrophage)，CSF2R，CSF2RAX，CSF2RAY，CSF2RX，CSF2RY，GM-CSF Receptor Alpha Subunit，GMCSFR，GMR，Granulocyte-Macrophage Colony-Stimulating Factor Receptor Alpha Chain，SMDP4，Colony Stimulating Factor 2 Receptor Alpha Subunit，CDw116，CD116 Antigen，Alpha-GM-CSF Receptor，AlphaGMR
Molekülhintergrund
GM-CSF R alpha(Granulocyte-macrophage colony-stimulating factor receptor subunit alpha) is also known as CSF2RA, CD116, GMR-alpha. Low affinity receptor for granulocyte-macrophage colony-stimulating factor. Transduces a signal that results in the proliferation, differentiation, and functional activation of hematopoietic cells. Hereditary pulmonary alveolar proteinosis (hPAP) is a rare disorder of pulmonary surfactant accumulation and hypoxemic respiratory failure caused by mutations in CSF2RA (encoding the granulocyte/macrophage colony-stimulating factor [GM-CSF] receptor α-chain [CD116]), which results in reduced GM-CSF-dependent pulmonary surfactant clearance by alveolar macrophages.
GM-CSF R alpha Produktliste
You Have Viewed 0 Of 0 Results
Klinische Arzneimittelinformation
| Englischer Name | Forschungscode | Forschungsphase | Firma | Indikationen | Klinische Studie |
|---|---|---|---|---|---|
| Mavrilimumab | CAM-3001; KPL-301; GM-CSFR; CAM3001 | Phase 3 Clinical | Csl Ltd | Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19); Giant Cell Arteritis; Pneumonia | Details |
| Anti-GMR CAR T-cell Therapy | Phase 2 Clinical | Kyoto Prefectural University Of Medicine, Shinshu University School of Medicine | Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile | Details | |
| CSF2RA gene-corrected macrophages(University of South Florida) | Phase 2 Clinical | Russian Academy Of Medical Sciences | Pulmonary Alveolar Proteinosis | Details | |
| STSA-1005 | STSA-1005; STSA1005 | Phase 1 Clinical | Staidson(Beijing) Biopharmaceuticals Co Ltd | Coronavirus Disease 2019 (COVID-19) | Details |